<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>The Photovoltaic Retina: A New Era for Sight Restoration</title>
    <style>
        body { font-family: 'Georgia', serif; line-height: 1.6; margin: 0; padding: 20px; background-color: #f9f9f9; color: #333; max-width: 800px; margin: 0 auto; }
        header { border-bottom: 2px solid #ddd; padding-bottom: 20px; margin-bottom: 30px; }
        h1 { color: #2c3e50; font-size: 2.2em; margin-bottom: 10px; }
        .subtitle { color: #34495e; font-size: 1.6em; margin-top: 0; font-weight: normal; }
        h2, h3 { color: #34495e; font-size: 1.8em; border-bottom: 1px solid #bdc3c7; padding-bottom: 5px; margin-top: 40px; }
        p { margin-bottom: 15px; text-align: justify; }
        .abstract { background-color: #ecf0f1; padding: 0 20px 20px 20px; border-left: 4px solid #3498db; margin: 20px 0; font-style: italic; }
        .abstract h2 { margin-top: 0; padding-top: 20px; }
        .references ol { list-style-type: decimal; padding-left: 20px; }
        .references li { margin-bottom: 15px; }
        .ref-justification { font-size: 0.9em; color: #555; font-style: italic; margin-top: 4px; }
        a { color: #3498db; text-decoration: none; }
        a:hover { text-decoration: underline; }
        sup { line-height: 1; }
        sup a { text-decoration: none; color: #3498db; font-size: 0.8em; vertical-align: super; }
        sup a:hover { text-decoration: underline; }
        .key-facts { background-color: #ffffff; padding: 20px; margin: 30px 0; border: 1px solid #ddd; }
        .key-facts h3 { margin-top: 25px; margin-bottom: 15px; border-bottom: none; padding-bottom: 0; font-size: 1.15em; }
        .key-facts h3:first-of-type { margin-top: 0; }
        .key-facts ul { list-style-type: disc; padding-left: 25px; margin: 0; }
        .key-facts li { margin-bottom: 10px; padding-left: 5px; }
        .article-image { float: right; max-width: 130px; height: auto; margin: 0 0 15px 20px; border: 1px solid #ddd; padding: 4px; background-color: #fff; }
        @media (max-width: 600px) { body { padding: 10px; } h1 { font-size: 1.8em; } .subtitle { font-size: 1.3em; } h2, h3 { font-size: 1.5em; } .article-image { float: none; display: block; margin: 20px auto; max-width: 90%; } }
    </style>
</head>
<body>
    <header>
        <img src="../images/Image_20251020_143358.jpg" alt="Article image" class="article-image">
       <h1>The Photovoltaic Retina</h1>
       <p class="subtitle"> A New Era for Sight Restoration</p>
    </header>
    <main>
       <p style="font-style: italic; color: #7f8c8d;">Monday, 20 October 2025 14:37</p>
        <section class="abstract">
            <h2>Abstract</h2>
           <p>A revolutionary electronic eye implant, the Prima system, has demonstrated unprecedented success in clinical trials, restoring the ability to read letters, numbers, and words for a significant majority of patients suffering from geographic atrophy, the advanced, incurable form of dry age-related macular degeneration. The wireless, subretinal microchip represents a paradigm shift in treating central vision loss, moving beyond previous generations of visual prosthetics to offer functional, high-acuity sight.</p>
        </section>
        <section class="key-facts">
            <h3>Historical Context</h3>
            <ul>
               <li>Approximately 200 million people worldwide are affected by AMD.</li>
               <li>Geographic atrophy affects an estimated 8 million people globally.</li>
               <li>The Argus II received CE mark in 2011 and FDA approval in 2013.</li>
               <li>Argus II's best reported grating acuity was 20/1262.</li>
               <li>The Argus II featured a 60-electrode array.</li>
            </ul>
            <h3>Recent Findings</h3>
            <ul>
               <li>The Prima microchip measures 2mm by 2mm and is 30µm thick.</li>
               <li>The Prima implant contains 378 independently controlled pixels.</li>
               <li>The PRIMAvera trial involved 38 elderly patients across 17 clinical sites.</li>
               <li>84% of participants could read letters, numbers, and words.</li>
               <li>The mean improvement in visual acuity was 25.5 letters on the ETDRS chart.</li>
            </ul>
        </section>
        <section>
           <h2>The Unmet Need of Central Blindness</h2>
           <p>Age-related macular degeneration (AMD) stands as the leading cause of irreversible blindness and severe visual impairment among older individuals in developed nations<sup><a href="#ref-8">8</a>,<a href="#ref-11">11</a></sup>. The global burden of this disease is immense, with estimates suggesting that approximately 200 million people worldwide are affected, a figure projected to rise to nearly 300 million by 2040<sup><a href="#ref-11">11</a></sup>. The condition progresses through stages, ultimately leading to late-stage AMD, which manifests in two primary forms: neovascular (wet) AMD and atrophic (dry) AMD<sup><a href="#ref-8">8</a></sup>. While anti-angiogenic therapies have transformed the prognosis for wet AMD, the advanced dry form, known as geographic atrophy (GA), has remained an intractable challenge for ophthalmologists<sup><a href="#ref-8">8</a></sup>. Geographic atrophy is characterised by the gradual, irreversible death of light-sensitive photoreceptor cells and the underlying retinal pigment epithelium (RPE) in the macula, the central part of the retina responsible for sharp, detailed vision<sup><a href="#ref-2">2</a>,<a href="#ref-15">15</a></sup>. This progressive loss of tissue results in a blind spot in the centre of the visual field, severely impairing the ability to perform essential daily tasks such as reading, driving, and recognising faces<sup><a href="#ref-2">2</a>,<a href="#ref-10">10</a></sup>. The condition affects an estimated 8 million people globally<sup><a href="#ref-2">2</a></sup>. For decades, the only advice for patients with advanced GA was to manage the progression with nutritional supplements, such as the AREDS2 formula, and to rely on low-vision aids<sup><a href="#ref-7">7</a></sup>. The absence of an effective treatment for GA has long represented one of the most significant unmet clinical needs in modern medicine<sup><a href="#ref-8">8</a></sup>.</p>
        </section>
        <section>
           <h2>A Microchip Half the Thickness of a Human Hair</h2>
           <p>The Prima system, developed by the US medtech company Science Corporation, represents a radical departure from previous attempts at sight restoration<sup><a href="#ref-3">3</a>,<a href="#ref-16">16</a></sup>. The core of the technology is a tiny, wireless, photovoltaic microchip, measuring just 2mm by 2mm and only 30µm (microns) thick, which is roughly half the thickness of a human hair<sup><a href="#ref-1">1</a>,<a href="#ref-3">3</a>,<a href="#ref-14">14</a>,<a href="#ref-16">16</a></sup>. This minuscule device is surgically implanted beneath the retina, in a procedure known as a vitrectomy, where surgeons create a 'trapdoor' under the macula to position the chip<sup><a href="#ref-1">1</a>,<a href="#ref-16">16</a></sup>. The Prima implant is a subretinal prosthesis, a critical distinction from earlier generations of 'bionic eyes'<sup><a href="#ref-2">2</a>,<a href="#ref-5">5</a></sup>. The chip contains 378 independently controlled pixels<sup><a href="#ref-5">5</a>,<a href="#ref-14">14</a></sup>. The system operates by bypassing the dead or damaged photoreceptors—the rods and cones—and directly stimulating the surviving inner retinal neurons, specifically the bipolar cells, which then transmit the visual information to the brain via the optic nerve<sup><a href="#ref-2">2</a>,<a href="#ref-5">5</a>,<a href="#ref-14">14</a></sup>. The implant itself is entirely cableless and autonomous<sup><a href="#ref-9">9</a></sup>. It is powered and activated by an external system comprising a pair of augmented reality (AR) glasses and a pocket-sized computer processor<sup><a href="#ref-3">3</a>,<a href="#ref-5">5</a></sup>. The glasses feature a front-facing camera that captures the visual scene, and an eye-facing projector that shines a pattern of pulsed, near-infrared light onto the implanted chip<sup><a href="#ref-5">5</a>,<a href="#ref-14">14</a></sup>. The photovoltaic pixels on the chip convert this infrared light into electrical current, which stimulates the retinal cells, effectively replacing the function of the lost photoreceptors<sup><a href="#ref-9">9</a>,<a href="#ref-14">14</a></sup>. The external processor allows the patient to adjust the image, including a crucial zoom feature to magnify text<sup><a href="#ref-1">1</a>,<a href="#ref-5">5</a></sup>.</p>
        </section>
        <section>
           <h2>Moving Beyond Coarse Vision</h2>
           <p>The Prima system’s success is best understood in the context of the history of visual prosthetics, a field that has struggled for decades to move beyond the restoration of rudimentary light perception<sup><a href="#ref-3">3</a></sup>. The most widely known predecessor was the Argus II Retinal Prosthesis System, manufactured by Second Sight Medical Products<sup><a href="#ref-2">2</a>,<a href="#ref-5">5</a></sup>. The Argus II, which received its CE mark in Europe in 2011 and FDA approval in the US in 2013, was an epiretinal device, meaning it was placed on the surface of the retina<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a>,<a href="#ref-5">5</a></sup>. It was designed to treat patients with profound vision loss from Retinitis Pigmentosa (RP), a different degenerative condition<sup><a href="#ref-2">2</a>,<a href="#ref-5">5</a></sup>. The Argus II featured a 60-electrode array<sup><a href="#ref-3">3</a>,<a href="#ref-5">5</a></sup>. While it was a monumental achievement, allowing patients to perceive spots of light, locate objects, and improve mobility, its visual acuity was limited<sup><a href="#ref-3">3</a>,<a href="#ref-4">4</a></sup>. The theoretical maximum acuity for the Argus II was approximately 20/1600, with the best reported grating acuity at 20/1262<sup><a href="#ref-3">3</a></sup>. The Prima device, with its subretinal placement and 378 pixels, represents a significant technological leap<sup><a href="#ref-5">5</a>,<a href="#ref-14">14</a></sup>. The subretinal position allows the implant to stimulate the retinal neurons in a way that more closely mimics the natural visual pathway, leading to a higher quality of vision<sup><a href="#ref-2">2</a></sup>. The difference in outcome is profound: where the Argus II restored basic light perception and object recognition, the Prima system has restored 'form vision' and the ability to read<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a>,<a href="#ref-10">10</a></sup>.</p>
        </section>
        <section>
           <h2>The Restoration of Functional Sight</h2>
           <p>The landmark clinical trial, known as PRIMAvera, involved 38 elderly patients across 17 clinical sites in five European countries, including the UK, Germany, France, Italy, and the Netherlands<sup><a href="#ref-1">1</a>,<a href="#ref-3">3</a>,<a href="#ref-9">9</a></sup>. The results, published in a peer-reviewed paper in The New England Journal of Medicine, were hailed by specialists as 'remarkable'<sup><a href="#ref-1">1</a>,<a href="#ref-3">3</a></sup>. The key finding was that 84% of the participants who received the implant were once again able to read letters, numbers, and words<sup><a href="#ref-1">1</a>,<a href="#ref-3">3</a>,<a href="#ref-6">6</a></sup>. This restored functional central vision to patients who had previously lost their sight in the affected eye due to geographic atrophy<sup><a href="#ref-1">1</a>,<a href="#ref-10">10</a></sup>. The mean improvement in visual acuity was measured at 25.5 letters on the ETDRS letter chart, which is equivalent to a gain of more than five lines<sup><a href="#ref-3">3</a></sup>. One patient demonstrated a maximum improvement of 59 letters, or 11.8 lines<sup><a href="#ref-7">7</a>,<a href="#ref-9">9</a></sup>. The ability to read, even with the aid of the system’s zoom feature, is a life-changing outcome that had been unattainable with previous technologies<sup><a href="#ref-1">1</a>,<a href="#ref-7">7</a></sup>. Patients in the trial reported being able to recognise playing cards and complete crossword puzzles, tasks that require a level of visual acuity far beyond simple light perception<sup><a href="#ref-4">4</a></sup>. Dr. Frank Holz, the lead author of the paper and lead investigator, stated that the implant represents a 'paradigm shift' in treating late-stage AMD<sup><a href="#ref-3">3</a></sup>. Max Hodak, the Chief Executive Officer of Science Corporation, noted that the restoration of the ability to fluently read had, to his knowledge, never been definitively shown in blind patients before this trial<sup><a href="#ref-7">7</a></sup>. Furthermore, the trial demonstrated a good safety profile, with no significant decline observed in the patients’ existing peripheral natural vision<sup><a href="#ref-3">3</a>,<a href="#ref-6">6</a></sup>.</p>
        </section>
        <section>
           <h2>The Path to Commercial Availability</h2>
           <p>Despite the overwhelmingly positive efficacy data, the path to widespread commercial availability involves rigorous regulatory scrutiny<sup><a href="#ref-4">4</a></sup>. The PRIMAvera study was specifically designed to demonstrate the device’s safety and efficacy to secure the Conformité Européenne (CE) mark, which is required for marketing the device across the European Union<sup><a href="#ref-7">7</a></sup>. Science Corporation submitted its application for the CE mark in June 2025, with a decision anticipated in 2026<sup><a href="#ref-4">4</a></sup>. In the United States, the Prima system received the Food and Drug Administration’s (FDA) Breakthrough Device status in 2023, a designation intended to expedite the development and review of technologies that offer a more effective treatment for life-threatening or irreversibly debilitating diseases<sup><a href="#ref-4">4</a></sup>. The company is also pursuing Humanitarian Use Device Designation in the US<sup><a href="#ref-4">4</a></sup>. The safety data from the trial, while generally positive, highlighted the inherent risks of intraocular surgery<sup><a href="#ref-9">9</a></sup>. The most common serious adverse events (SAEs) reported among the 38 patients were retinal break, which occurred in eight patients, followed by hypertony (elevated intraocular pressure) and subretinal haemorrhage, each occurring in six patients<sup><a href="#ref-9">9</a></sup>. These events primarily occurred within the first two months post-implantation, with 95% of the serious adverse events resolving within two months<sup><a href="#ref-3">3</a></sup>. The long-term success of the device will depend not only on its technical performance but also on the patient’s commitment to post-operative training sessions, which are essential for the brain to learn how to merge the prosthetic central vision with the patient’s remaining natural peripheral vision<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup>. The ability of the brain to integrate these two distinct visual inputs is a key factor in the overall functional outcome<sup><a href="#ref-10">10</a></sup>.</p>
        </section>
        <section>
            <h2>Conclusion</h2>
           <p>The successful clinical trial of the Prima electronic eye implant marks a pivotal moment in the treatment of age-related macular degeneration and the broader field of neuro-engineering<sup><a href="#ref-3">3</a>,<a href="#ref-7">7</a></sup>. By employing a wireless, photovoltaic microchip to directly stimulate the surviving retinal neurons, the technology has overcome the limitations of previous visual prosthetics, restoring not just light perception but functional, high-acuity vision, including the ability to read<sup><a href="#ref-1">1</a>,<a href="#ref-6">6</a>,<a href="#ref-9">9</a></sup>. The results offer profound hope to the millions of elderly individuals worldwide who suffer from geographic atrophy, a condition for which no other treatment exists<sup><a href="#ref-2">2</a>,<a href="#ref-8">8</a></sup>. As the device moves through the final stages of regulatory approval in Europe and the United States, the focus shifts to the logistical and economic challenges of making this complex, life-altering technology accessible to the global population in need<sup><a href="#ref-4">4</a></sup>. The restoration of central vision represents a significant step toward mitigating the devastating personal and public health impact of central blindness<sup><a href="#ref-12">12</a></sup>.</p>
        </section>
        <section class="references">
            <h2>References</h2>
            <ol>
               <li id="ref-1">
                   <a href="https://www.theguardian.com/science/2025/oct/20/experts-hail-remarkable-success-of-electronic-implant-in-restoring-sight" target="_blank">Experts hail ‘remarkable’ success of electronic implant in restoring sight</a>
                   <p class="ref-justification">Supports the device name, trial success rate (84% reading ability), size (half the thickness of a human hair), the condition treated (dry AMD/geographic atrophy), and the multi-country trial scope.</p>
                </li>
               <li id="ref-2">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHTbwoT3D9_QE0zK3LUbBowF19cTe20mkxPRwh35BdVLB7kj0aaye5mYdvvMRGFS3BrJe4OZC1W8a3SFJ9Tr7fBCXIp4ZrIbPfWtV7LC5dyMQYrkIZRi2f-WW-hBtCjOJDVB7Rb3P7gV_2cHvyl" target="_blank">Prosthetic Visual Acuity with the PRIMA System in Patients with Atrophic Age-related Macular Degeneration at 4 years follow-up</a>
                   <p class="ref-justification">Provides detail on the specific condition (geographic atrophy), the subretinal placement, the mechanism (photovoltaic neurostimulation of bipolar cells), and the global prevalence of GA (8 million people).</p>
                </li>
               <li id="ref-3">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQH9ii1HJbz_21UsRvf4E_8VdPN3qZaz3unIiNMoNz2WSlZE-xObsrmAP9ei6C6ZiujISdi1HbpECbSBeH7jOmfXFDWp65ec-X0YdZjj4gfqVSkqJn7E3c70tW8kCHxwBtHvISyyTKzyO_ejZFckHMxC94QMdGZcHSN1TI4xGbFuaC_OrOJ_7jdp9Pg0xvZCtyf6BCKBfD1KhfORJ99fak7JXxKKTCXvz4h1DfQaRLw8oyDabbRGDpJKP0582QH9NlRBOGUdrXuXk1ZZk0_3ae9kI-YbLsS46iU9_uZi0f1oE_xFMk7JE9ZINIGWbkV9PB8YL1_iGP9Qii14rnZWHWE10xNZnUMtKlgmViVnE_14dltGefOsGcQyQMDYKr5nw_KX9fAqK-y4ph1JWP3w3rHymk3sZkoDPaLhv184_pl9S6Q8sytDtw4J8LfGRFhEW1Y=" target="_blank">Science Corp.'s PRIMA BCI Implant Restores Functional Central Vision to Patients with Geographic Atrophy Caused By Age-Related Macular Degeneration, a Leading Cause of Blindness, The New England Journal of Medicine Reports</a>
                   <p class="ref-justification">Confirms the publication in NEJM, the mean visual acuity improvement (25.5 letters/5 lines), the 84% success rate, the device size (2x2mm, 30µm), the company (Science Corporation), and quotes from Dr. Frank Holz.</p>
                </li>
               <li id="ref-4">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGwhMB0xXZxX5fSw7b_jMTv-w7c7KIkazThLKziufU6zDVKBGNvA5bFB1RjPtv7qNtAA2EdsDX8qPoEl2_rxVx7o_555s6UFYqSlVcGepNSPUOaPumECy72t4n4NI8HiqDlXSeoQuukVymG7fYmWnd_CBiKXy78Be0=" target="_blank">Science Submits CE Mark Application for PRIMA Retinal Implant – A Critical Step Towards Making It Available To Patients</a>
                   <p class="ref-justification">Details the regulatory status (CE mark application in June 2025, decision expected in 2026, FDA Breakthrough Device status in 2023), the original research at Stanford, and patient activities (recognising playing cards, crossword puzzles).</p>
                </li>
               <li id="ref-5">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQFtSifCD4uh22ic29wh1Jckjzryu2WS_--vE96Nam-7A4kDauO1u83z9xjmNMELQAI2joOP40LmDC_l1ZTqmP22xLxBDqrSVxDvWJyfpDBWqKNLVr39Q78bE6L0SJTatFsP2g==" target="_blank">PRIMA Visual Prosthesis - Science Corporation</a>
                   <p class="ref-justification">Explains the technology: 378 light-powered pixels, wireless, subretinal placement, bypassing photoreceptors to stimulate bipolar cells, and the components (implant, AR glasses, pocket processor).</p>
                </li>
               <li id="ref-6">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHxle1DDHwtDoCsKujP2HMvvcXgvtxc7RQFHX-rhCSzmtVtjFm5koP-67EkhXMMJOdfGyz_Wm6LaUZgpDNNOQWc-HCYUzQ1GgbuyZAJbZOnsY_CqkJh4FoyeRW3MAsnSyIvaHOjk5p64nVvCoQnXC9sojUPm6fKbVsg6XQZkOXwUQywdiryUx7PbdhYBY3Nja1m72QQ54g=" target="_blank">Groundbreaking Eye Technology Restores Reading Vision in the Blind</a>
                   <p class="ref-justification">Confirms the 84% success rate in reading letters/words, the 38-patient trial size, and the involvement of Moorfields Eye Hospital.</p>
                </li>
               <li id="ref-7">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQE6IalwcCuMr97_ur59XNErxovk6zS4L4aTo_kApMzsX3O8UxtXy_vlievAhnMP03VnP_SYutvmM862toNgpP3lzOIkNRsYzeZMyvZ8hUMTorOGJNJXlS5sbXtTKnAR5lNwMr_QwxlaYsrJreGDn-IVN0v-rXOKm9k=" target="_blank">Science Announces Positive Preliminary Results For Vision Restoration In Pivotal Clinical Trial</a>
                   <p class="ref-justification">Provides quotes from Max Hodak and Professor Frank Holz regarding the restoration of 'form vision' and the ability to 'fluently read,' and confirms the trial's goal for CE mark approval.</p>
                </li>
               <li id="ref-8">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGgpBh0bqGXFYBVIimnNM9Zu5Hag6roEY1-nv5AfngzUKqldBz3pQPnMgds566Fq4JzqzY_Sno6n8xDZOI6dHDWFG4O-f71ffnoIio2S87q8GLppoZfmknFpNV4qSNXlcoas8EyRVOxNdHHt_M=" target="_blank">Dry age-related macular degeneration: A currently unmet clinical need</a>
                   <p class="ref-justification">Establishes the context of AMD as a leading cause of irreversible blindness and the lack of therapy for advanced dry AMD (geographic atrophy).</p>
                </li>
               <li id="ref-9">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQF7I-qkOVgWzgFiVze34VzfLcvY0u7DYO5SnHFU4DOR3D8aae_ZY0i60-J76GmewBFy-iUBCl6YXeL7VhVi_-u2ZHIcnztZsw8UKMMklK4dBujfHy05bGrCTJt8NYq2_cQI_tpAO2eZOyz7Pwhj8DP8FT9i4L6csR5tWVKH-VxZtam-IXe9n17osrD5uMtrcNAMfWJPK9DGtjj8YF6S-g==" target="_blank">Trial Shows Positive Results for Retinal Implant</a>
                   <p class="ref-justification">Details the most common serious adverse events (retinal break, hypertony, subretinal haemorrhage) and confirms the trial size (38 patients) and the need for post-operative training.</p>
                </li>
               <li id="ref-10">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHfcZQF18kq7esN27h10w4w0D_gqq0luR7rpB7M-S5Uqia7lJKd5H28GL-9H10h2azurPJCtUpJgr5cZB08mxebeb6zs2_39ZypflWBXV_zVItLo3IlpQoCBPfOQIGbrPODBqzbEg-qjkExkHKPy2-zrIUBcPr38PTG0hrz9Tqg4x5ahvYbKObkkoRCW2abwOhnv_TUmiE_S1MLAIX7kRl983" target="_blank">Inspiring Hope: The bionic eye returning vision to the blind | Ophthalmology | Stanford Medicine</a>
                   <p class="ref-justification">Explains the concept of 'form vision,' the role of Professor Daniel Palanker, the merging of prosthetic and natural vision, and the severity of vision loss in the trial patients (20/400 or worse).</p>
                </li>
               <li id="ref-11">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGWKqWoqmQLv08XZTZbRsE989VHCtGno6BxmGlnQyyX146eZkKdphOJPfv4iHyXJePB9yaPQt7cKgaUyRXvaOqJsk8boWxMcGM3ZgrqXsbh5r2p538jhnwB9JrY3X4eQryn5QqdbiK1rUGcVB4=" target="_blank">Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment</a>
                   <p class="ref-justification">Provides global prevalence statistics for AMD (200 million, rising to 300 million by 2040) and confirms it is the most common cause of irreversible blindness in older persons.</p>
                </li>
               <li id="ref-12">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGHi3jtIHi5U_Be_GiJNb4SH-FN3koEpj2t4QEBvGeu5pzyhjNSrlSu_ChRyZPJ4DRZxOXxBV8K-MGJz4z8bnz_jFMYvbftTDPQnHIY2BC1I5LQAbIlc_hpsqcB9AFw60m2LnUQ2xSMsv8Ee6rCPdkyQKLRpbY9Ua_91qHmOx_NSOm6RkRmLVb7HESivndoECBNKuqvkVQ0KA4g" target="_blank">Dry age-related macular degeneration: The second city of AMD</a>
                   <p class="ref-justification">Used to support the severity of AMD's impact and its comparison to other major diseases like Alzheimer's.</p>
                </li>
               <li id="ref-13">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHH78Hf0xuMjwZUemn2uIRlqerfED2Mhfu61WdQudkamHg3nqcq-91qFrC_lgZ8T7gv6sChVj25ZJ_J1DJCsI9JK09lX4fuyl-QuufTmg7Ae1PavG9cGsq2YrkEeNCYVsuH-62YNOJ-WkBbxVYt0hwNyIGxcBY8Vnj9vJTekt3YtUODcGTD5625ZN4nDbyQxHpTiz8=" target="_blank">Real-life Story of the 'Bionic Eye,' the Argus II</a>
                   <p class="ref-justification">Provides historical context for the Argus II, including its first implantation in 2007 and its classification as an epiretinal implant.</p>
                </li>
               <li id="ref-14">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHbc1Sj9e5jF-NHZAVzVWCR5wYkmsD9JZ-vRjt9-pWgAA1AAjtuCqnqCr2ATDy_FPj_pYv7A3bl98mMy_VItjY1DSL9aiM_S07VYQz3VXtlnREyEj9iHmFCFPsaHg==" target="_blank">Simulation of prosthetic vision with PRIMA system and enhancement of face representation</a>
                   <p class="ref-justification">Confirms the Prima implant's size (2x2mm), thickness (30 μm), pixel count (378), and the mechanism of using near-infrared light to stimulate bipolar cells.</p>
                </li>
               <li id="ref-15">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQEEcN7THEThXcqYNbulqNb2x_nOYryvhIvhAX0N9KvJiSL-6sYw0LcP5fGjxPGchQSX7RJw1_MHXMuk33se4T9j66hYON6h7LPvk3fqq_EVoUV3xGS9Ts574ENaNOE1J_jN4mEG_ELnGDSV3YC_9sXhOgQsl8OzszcLYlKvDgB5Gbh-f6a-3f4rR3Ao1yYed1Fybg=" target="_blank">Dry Age-Related Macular Degeneration - Epidemiology Forecast - 2034</a>
                   <p class="ref-justification">Used to define geographic atrophy as the stage of irreversible vision loss caused by the depletion of RPE and photoreceptors.</p>
                </li>
               <li id="ref-16">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQGFO1OVc5PQnp9rRRyC53MWc9n8A19sPnDFouF6Gr_vEtmcdj4KAxZm2YjibUURqHiJfvCe20Q0coL0MKKP1VTyudsFNMzsOZ0KeTXZWQG7eI7kytLXTSHFl7Shz9k6M0bpF1bncMm9BRkTOf1Q9cTOb_ht1O0hq0MITbXSrRxCsLfd69qgf19RPhaVElFHnPU9Aycl30X6" target="_blank">What is Prima? The device helping those with vision loss to read again</a>
                   <p class="ref-justification">Confirms the surgical procedure involves a vitrectomy and creating a 'trapdoor' under the retina.</p>
                </li>
               <li id="ref-17">
                   <a href="https://vertexaisearch.cloud.google.com/grounding-api-redirect/AUZIYQHy4PzDb9-yD3XOjZvGiAqLVn7OwQA0QRuUL2lPa4tikS4fkeREjcJTDvSiCLGiCyCA4otjICnx6xvXC18oq8PrJGylU7ULlL-rPeEOnFkAUzCGYpw8G99IbgossYYd-LXQ9nX5XQEVlnMihQBesks03zVbDkGgP9qKiZsMzIKGIG-Lpqn5rV0wjQBnCgRc2IxoJZgPX3Bbl6Y10rSpnwldXZURiQ=" target="_blank">FDA approves sub-retinal implant clinical feasability study</a>
                   <p class="ref-justification">Confirms the original developer was Pixium Vision and the initial US feasibility study was approved by the FDA in 2018.</p>
                </li>
            </ol>
        </section>
    </main>
</body>
</html>
